Citi Maintains a Buy Rating on Gilead Sciences (GILD)

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the top low volatility healthcare stocks to buy now. In a report released on July 21, Geoff Meacham from Citi maintained a Buy rating on Gilead Sciences, Inc. (NASDAQ:GILD) with a price target of $125.00.

On July 14, Gilead Sciences, Inc. (NASDAQ:GILD) presented new data on the twice-yearly Lenacapavir (Yeztugo®) for HIV Prevention at the IAS 2025.

The company reported that new data from the PURPOSE trials showed that Lenacapavir was well-tolerated and effective across a range of populations, including lactating and pregnant women, young people, and adolescents.

The data also showed that the twice-yearly injectable PrEP was preferred compared to daily oral medication among PURPOSE trial participants.

Gilead Sciences, Inc. (NASDAQ:GILD) is a biotech company that advances medicines to prevent and treat serious diseases such as cancer, immunodeficiency virus (HIV), viral hepatitis, and COVID-19.

Its portfolio of drugs focuses on medical areas with unmet needs and includes AmBisome, Atripla, Biktarvy, Cayston, Complera, and others. Gilead Sciences, Inc. (NASDAQ:GILD) operates in over 35 countries.

While we acknowledge the potential of GILD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.